TARGETED TRAILBLAZER Trademark
Trademark Overview
On Tuesday, September 9, 2025, a trademark application was filed for TARGETED TRAILBLAZER with the United States Patent and Trademark Office. The USPTO has given the TARGETED TRAILBLAZER trademark a serial number of 99383499. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, June 1, 2026. This trademark is owned by Bicycletx Limited. The TARGETED TRAILBLAZER trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceutical compounding services; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in connection with respiratory disease; pharmaceutical compounding services in connection with cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease
Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services being scientific research in the nature of conducting clinical trials for others, conducting scientific feasibility studies, technical research in the field of pharmaceutical studies in the fields of development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; scientific research services; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hemat...
Pharmaceuticals for use in oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical preparations for suppressing tumors; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical products and preparations for use in relation to oncology; pharmaceutical products and preparations for use in relation to ophthalmology; pharmaceutical products and preparations for use in relation to neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and prevention of respiratory disease; pharmaceutical products and preparations for the treatment and prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and prev...
General Information
| Serial Number | 99383499 |
| Word Mark | TARGETED TRAILBLAZER |
| Filing Date | Tuesday, September 9, 2025 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Monday, June 1, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 23, 2026 |
Trademark Statements
| Goods and Services | Pharmaceutical compounding services; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in connection with respiratory disease; pharmaceutical compounding services in connection with cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease |
| Goods and Services | Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services being scientific research in the nature of conducting clinical trials for others, conducting scientific feasibility studies, technical research in the field of pharmaceutical studies in the fields of development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; scientific research services; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical research and development in the field of oncology; medical research and development in the field of ophthalmology; medical research and development in the field of neurology; medical research and development in the field of anti-infective pharmaceuticals; medical research and development in the field of respiratory disease; medical research and development in the field of cardiovascular disease; medical research and development in the field of metabolic disease; medical research and development in the field of antiviral drugs; medical research and development in the field of diagnostics and imaging; medical research and development in the field of renal disease; medical research and development in the field of gastrointestinal disease; medical research and development in the field of muscular skeletal disease; pharmaceutical drug development services; pharmaceutical drug development services in the field of oncology; pharmaceutical drug development services in the field of ophthalmology; pharmaceutical drug development services in the field of neurology; pharmaceutical drug development services in the field of anti-infectives; pharmaceutical drug development services in connection with respiratory disease; pharmaceutical drug development services in connection with cardiovascular disease; pharmaceutical drug development services in connection with metabolic disease; pharmaceutical drug development services in connection with the treatment and prevention of viral infections; pharmaceutical drug development services in connection with diagnostics and imaging; pharmaceutical drug development services in connection with renal disease; pharmaceutical drug development services in connection with gastrointestinal disease; pharmaceutical drug development services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid |
| Goods and Services | Pharmaceuticals for use in oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical preparations for suppressing tumors; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical products and preparations for use in relation to oncology; pharmaceutical products and preparations for use in relation to ophthalmology; pharmaceutical products and preparations for use in relation to neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and prevention of respiratory disease; pharmaceutical products and preparations for the treatment and prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and prevention of metabolic disease; pharmaceutical products and preparations for the treatment and prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging for the prevention and treatment of cancer; pharmaceutical products and preparations for the treatment and prevention of renal disease; pharmaceutical products and preparations for the treatment and prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and prevention of muscular skeletal disease |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, September 9, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, September 9, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, September 9, 2025 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Bicycletx Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 24 - NOT AVAILABLE |
| Address | Cambridge CB21 6GS
GB |
Trademark Events
| Event Date | Event Description |
| Tuesday, September 9, 2025 | NEW APPLICATION ENTERED |
| Tuesday, September 9, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, September 9, 2025 | APPLICATION FILING RECEIPT MAILED |
| Thursday, November 20, 2025 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Thursday, November 20, 2025 | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED |
| Friday, December 12, 2025 | ASSIGNED TO EXAMINER |
| Friday, December 19, 2025 | NON-FINAL ACTION WRITTEN |
| Friday, December 19, 2025 | NON-FINAL ACTION E-MAILED |
| Friday, December 19, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, March 10, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, March 10, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, March 10, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, March 30, 2026 | FINAL REFUSAL WRITTEN |
| Monday, March 30, 2026 | FINAL REFUSAL E-MAILED |
| Monday, March 30, 2026 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, May 13, 2026 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Wednesday, May 13, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, May 13, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, May 22, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
